CD19

NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...

SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...

SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...

BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

WALTHAM, Mass., June 2, 2026 Zenas BioPharma, Inc. announced positive results from its registrational Phase 3 INDIGO trial evaluating...